Trial Success Buzz: Recent chatter on social media has been ignited by Alumis Inc.'s announcement of positive Phase 3 trial results for their psoriasis drug, envudeucitinib. Many users are excited about the reported superior skin clearance rates, with the stock seeing a significant surge as a result. The news has sparked intense interest among investors tracking biotech developments.
Insider Confidence: Alongside the trial data, discussions on social media have also focused on insider purchases at Alumis Inc. Several posts highlight these buys as a sign of strong internal confidence, fueling speculation about future catalysts. This has added to the heightened attention on the stock's trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Alumis Inc. Insider Trading Activity
Alumis Inc. insiders have traded $ALMS stock on the open market 26 times in the past 6 months. Of those trades, 26 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ALMS stock by insiders over the last 6 months:
- SRINIVAS AKKARAJU has made 14 purchases buying 1,265,253 shares for an estimated $9,069,492 and 0 sales.
- JAMES B. TANANBAUM has made 4 purchases buying 507,874 shares for an estimated $3,094,725 and 0 sales.
- CAPITAL MANAGEMENT VI LLC FORESITE has made 4 purchases buying 507,874 shares for an estimated $3,094,725 and 0 sales.
- LABS, LLC FORESITE has made 4 purchases buying 507,874 shares for an estimated $3,094,725 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Alumis Inc. Hedge Fund Activity
We have seen 65 institutional investors add shares of Alumis Inc. stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WOODLINE PARTNERS LP added 1,558,660 shares (+809.7%) to their portfolio in Q3 2025, for an estimated $6,219,053
- MADISON AVENUE PARTNERS, LP removed 1,424,492 shares (-77.3%) from their portfolio in Q3 2025, for an estimated $5,683,723
- TANG CAPITAL MANAGEMENT LLC removed 829,788 shares (-41.6%) from their portfolio in Q3 2025, for an estimated $3,310,854
- VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 674,163 shares (-41.6%) from their portfolio in Q3 2025, for an estimated $2,689,910
- VANGUARD GROUP INC added 625,404 shares (+18.4%) to their portfolio in Q3 2025, for an estimated $2,495,361
- CANTOR FITZGERALD, L. P. removed 559,201 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,231,211
- UBS GROUP AG removed 444,880 shares (-36.8%) from their portfolio in Q3 2025, for an estimated $1,775,071
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Alumis Inc. Analyst Ratings
Wall Street analysts have issued reports on $ALMS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/18/2025
- Morgan Stanley issued a "Overweight" rating on 08/15/2025
- Wells Fargo issued a "Overweight" rating on 07/25/2025
To track analyst ratings and price targets for Alumis Inc., check out Quiver Quantitative's $ALMS forecast page.
Alumis Inc. Price Targets
Multiple analysts have issued price targets for $ALMS recently. We have seen 4 analysts offer price targets for $ALMS in the last 6 months, with a median target of $18.5.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $20.0 on 12/18/2025
- Terence Flynn from Morgan Stanley set a target price of $22.0 on 08/15/2025
- Derek Archila from Wells Fargo set a target price of $17.0 on 07/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
